Effects of N-PEP-12 on memory among older adults

International Clinical Psychopharmacology

Volumn 20, Issue 2, 2005, Pages 97-100

  Crook, Thomas H ^a,d   Ferris, Steven H ^b   Alvarez, X Anton ^c   Laredo, Martha ^c   Moessler, Herbert ^d  

^a Psychologix Inc   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Centro de Investigacion Biomedica EuroEspes   (Spain)

^d E8EWE Pharma ^*  (United States)

Author keywords

Age related memory loss; Memory; N PEP 12; Neuropeptides

Indexed keywords

CEREBROLYSIN; N PEP 12; NEUROPEPTIDE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; AGITATION; ALZHEIMER DISEASE ASSESSMENT SCALE; ANEMIA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGIT CANCELLATION TEST; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DYSESTHESIA; DYSPEPSIA; FACE DYSESTHESIA; FEMALE; FINGER SPAN TEST; GENERAL CONDITION IMPROVEMENT; HEADACHE; HUMAN; HYPOTENSION; MALE; MEMORY; MEMORY DISORDER; NEUROPSYCHOLOGICAL TEST; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; SPAIN; SUBMANDIBULAR DYSESTHESIA; SYNDROM KURZ TEST; VERBAL FLUENCY TEST;

AGED; AMINO ACIDS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MEMORY; MEMORY DISORDERS; MIDDLE AGED; NOOTROPIC AGENTS; TREATMENT OUTCOME;

EID: 14844363562     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200503000-00006     Document Type: Article

References (23)

1. Akai F, Hiruma S (1992). Neurotrophic factor-like effect of FPF1070 on septal cholinergic neurons after transactions of fimbria-foRNix in the rat brain. Histol Histopathol 7:213-221.
2. Alvarez A (2003). N-PEP-12 - a neuropeptide preparation enhances cognitive function and activates bioelectrical activity in healthy elderly humans. EBEWE Clinical Study Report, pp. 1-19.
3. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association.
4. Baskys A, Wotowicz M (1994). Effects of brain tissue hydrolysate on synaptic transmission in the hippocampus. Pharmacol Biochem Behav 49: 1105-1107.
5. Boado R, Dafang W, Windisch M (1999). In vivo upregulation of the blood-brain barrier GLUT-1 glucose transporter by brain-derived peptides. Neurosci Res 34:217-224.
6. Crook T, Larrabee G (1988). Interrelationships among everyday memory tests: stability of factor structure with age. Neuropsychology 2:1-12.
7. Crook T, Tinklenberg J, Yesavage J, Petrie W, Nunzi M, Massari D (1991). Effects of phosphatidylserine in age-associated memory impairment. Neurology 41:644-649.
8. Eder P, Reinprecht I, Schreiner E, Scifitsch G, Windisch M (2001). Increased density of glutamate receptor subunit 1 due to Cerebrolysin treatment: an immunohistochemical study of aged rats. Histochem J 33: 605-612.
9. Erzigkeit H (1989). The SKT - a short cognitive performance test as an instrument for the assessment of clinical efficacy of cognitive enhancers. In: Bergner M, Reisberg R (editors): Diagnosis and Treatment of Senile Dementia. Heidelberg: Springer Verlag.
10. Gschanes A, Windisch M (1998). The influence of Cerebrolysin and E021 on spatial navigation of 24 month-old rats. J Neural Trans 53: 313-321.
11. Hartbauer B, Hutter-Paier B, Skofitsch, Windisch (2001). Antiapoptic effects of the peptidergic drug Cerebrolysin on primary cultures of embryonic chick cortical neurons. J Neural Transm 108:459-473.
12. Hutter-Paier B, Windisch M, Moessler H (2004). Long-term treatment of aged rats with N-PEP-12 - a dietary supplement containing neuroprotective biopeptides (manuscript in preparation).
13. Leuschner F (1980a). Acute Toxicity Study of Cerebrolysin Double Concentrated by Oral Administration to Mongrel Dogs. Hamburg, Germany: Study Report, Laboratory of Pharmacology and Toxicology.
14. Leuschner F (1980b). Acute Toxicity Study of Cerebrolysine Double Concentrated by Oral Administration to Sprague-Dawley Rats. Hamburg, Germany: Study Report, Laboratory of Pharmacology and Toxicology.
15. Lezak MD (1983). Neuropsychological Assessment, Oxford: Oxford University Press.
16. McKhann G, Drachmen D, Folstein M, Katzman R, Price D, Stadlan E (1984). Clinical diagnosis of Alzheimer's disease; Report of the NINCDS-ADRDA work group. Neurology 34:39-44.
17. Mohs R (1994). Administration and Scoring Manual for the Alzheimer's Assessment scale, rev edn. New York, NY: The Mount Sinai School of Medicine.
18. Mohs R, Knopman D, Peterson R, Ferris S, Ernesto N, Grundmam M, et al. (1997). Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's disease assessment scale (ADAS) that broaden its scope. Alzheimer's Dis Relat Disord 11:313-321.
19. Panisset M, Gauthier S, Moessler H, Windisch M, The Cerebrolysin Study Group (2002). Cerebrolysin in Alzheimer's disease: a randomized, double blind, placebo-controlled trial with a neurotrophic agent. J Neural Transm 109:1089-1104.
20. Ruether E, Husmann R, Kinzler E, Diabl E, Kingler D, Spatt J, et al. (2001). A 28 week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease. Int Clin Psychopharmacol 16:253-263.
21. Shader R, Harmatz J, Salzman C (1974). A new scale for clinical assessment in geriatric populations: Sando Clinical Assessment-Geriatric (SCAG). J Amer Geriat Assoc 22:107-113.
22. Wechsler D (1981). Wechsler Adult Intelligence Scale, rev. edn. New York, NY: Psychological Corporation.
23. Wolfson C, Oremus M, Sukla V, Momoli F, Demers L, Perrault A, Moride Y (2002). Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence sythesis of the published data on their efficacy and cost-effectiveness. Clin Ther 6:862-886.